BioCryst Receives Fast-Track Status for Peramivir, But Does It Justify The Stock's Appreciation? (BCRX) 2 comments
January 18, 2006
| about: BCRX
-
Font Size:
-
Print
- TweetThis
Yesterday, the FDA granted Fast Track status to BioCryst’s (ticker: BCRX) influenza drug, peramivir. Investors were overjoyed by the news, sending the stock up 18% on the day. Was the market’s reaction to the news rational? Is a Fast Track designation worth $90 million? Investors seem to think so – that’s how much they added to BioCryst’s market capitalization on the news.
To address the question of the value of Fast Track designation, let’s first look at what “fast track
Related Articles
|


























This article has 2 comments: